Medical Care and Payment for Diabetes in China: Enormous Threat and Great Opportunity
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The Diabetes Impact Study followed up a large national population-based screening study to estimate the use of and expenditures for medical care caused by diabetes in China and to ascertain the use and cost of essential basic medicines and care. METHODS: In 2009-10, the study team interviewed 1482 adults with diabetes and 1553 adults with glucose tolerance in the normal range from population-based random samples at 12 sites in China. The response rate was 67%. FINDINGS: After adjusting for age, sex, and urban/rural location, people with diabetes received 1.93 times more days of inpatient treatment, 2.40 times more outpatient visits, and 3.35 times more medications than people with normal glucose tolerance (all p<0.05). Adjusted expenditures for medical care were 3.38 times higher among people with diabetes than among people with normal glucose tolerance (p<0.01, unadjusted 3.97). Persons who were diagnosed with ≥ 10 years prior to the survey paid 3.75 times as much for medical care as those with ≤ 5 years of diagnosed diabetes. Among persons with diabetes, 45.2% took medication to control blood sugar, 21.1% took an antihypertensive medicine, 22.4% took daily aspirin, and 1.8% took a statin. Over the three months before the interview, 46.1% of persons with diabetes recalled seeing a doctor, 48.9% recalled a blood pressure measurement, and 54.5% recalled a blood sugar test. Over the year preceding the interview, 32.1% recalled a retinal screening and 17.9% recalled a foot examination. CONCLUSIONS: In China, health care use and costs were dramatically higher for people with diabetes than for people with normal glucose tolerance and, in relative terms, much higher than in industrialized countries. Low-cost generic medicines that would reduce diabetes expenditures were not fully used.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Documenting access to care is particularly important because complications from DM, which can be devastating, could largely be prevented by wider use of inexpensive generic medicines, such as metformin, sulphonylureas, statins, angiotensin-converting-enzyme (ACE)-inhibitors, and other classes of blood pressure-lowerin…”
BackgroundEconomic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Prevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031 · cited 4×
“In 2006, China had an estimated 92 million persons with DM, [6] 9.”
BackgroundInfluentialSelf-citationLaw, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
The burden and costs of chronic diseases in low-income and middle-income countries.
Abegunde, D. O., Mathers, C. D., Adam, T., Ortegon, M., & Strong, K. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61696-1 · Cited by 1,603 · cited 1×
“The expenditure ratios reported here imply, as do analyses using different methods, [37,38] that in LMICs the economic burden of DM may constrain the availability of medical resources for other health conditions and retard national economic growth in future years.”
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Law, M. R., Wald, N. J., Morris, J. K., & Jordan, R. E. (2003) · BMJ · doi:10.1136/bmj.326.7404.1427 · Cited by 1,232
Global healthcare expenditure on diabetes for 2010 and 2030
Zhang, P., Zhang, X., Brown, J., Vistisen, D., Sicree, R., Shaw, J., & Nichols, G. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.01.026 · Cited by 1,145
Self-citationGlobal guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Cited by
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
Seuring, T., Archangelidi, O., & Suhrcke, M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0268-9 · Cited by 837
The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study
Bommer, C., Heesemann, E., Sagalova, V., Manne-Goehler, J., Atun, R., Bärnighausen, T., & Vollmer, S. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30097-9 · Cited by 816
Epidemiology of diabetes and diabetic complications in China
Ma, R. C. W. (2018) · Diabetologia · doi:10.1007/s00125-018-4557-7 · Cited by 491
A machine learning-based framework to identify type 2 diabetes through electronic health records
Zheng, T., Xie, W., Xu, L., He, X., Zhang, Y., You, M., Yang, G., & Chen, Y. (2017) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2016.09.014 · Cited by 380
IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes
da Rocha Fernandes, J., Ogurtsova, K., Linnenkamp, U., Guariguata, L., Seuring, T., Zhang, P., Cavan, D., & Makaroff, L. E. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.016 · Cited by 373
Self-citation
Metadata
- Authors
- Yang, W., Zhao, W., Xiao, J., Li, R., Zhang, P., Kissimova-Skarbek, K., Schneider, E., Jia, W., Ji, L., Guo, X., Shan, Z., Liu, J., Tian, H., Chen, L., Zhou, Z., Ji, Q., Ge, J., Chen, G., & Brown, J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-09-26
- Volume
- 7
- Issue
- 9
- Pages
- e39513
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2063735093
- Cited by
- 90
- References
- 17
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medical Care and Payment for Diabetes in China: Enormous Threat and Great Opportunity. https://app.cochat.ai/papers/10.1371/journal.pone.0039513
- The paper
- Yang, W., Zhao, W., Xiao, J., Li, R., Zhang, P., Kissimova-Skarbek, K., Schneider, E., Jia, W., Ji, L., Guo, X., Shan, Z., Liu, J., Tian, H., Chen, L., Zhou, Z., Ji, Q., Ge, J., Chen, G., & Brown, J. (2012). Medical Care and Payment for Diabetes in China: Enormous Threat and Great Opportunity. PLoS ONE. https://doi.org/10.1371/journal.pone.0039513
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.